Preventing hospital admissions by reviewing medication (PHARM) in primary care: design of the cluster randomised, controlled, multi-centre PHARM-study

<p>Abstract</p> <p>Background</p> <p>Medication can be effective but can also be harmful and even cause hospital admissions. Medication review or pharmacotherapy review has often been proposed as a solution to prevent these admissions and to improve the effectiveness an...

Full description

Bibliographic Details
Main Authors: van den Bogert Sander CA, Goudswaard Alex N, Jonkhoff Andries R, de Koning Fred HP, Leendertse Anne J, de Gier Han J, Egberts Toine CG, van den Bemt Patricia MLA
Format: Article
Language:English
Published: BMC 2011-01-01
Series:BMC Health Services Research
Online Access:http://www.biomedcentral.com/1472-6963/11/4
id doaj-6567bb6492224a13ad96cdcc70bac5de
record_format Article
spelling doaj-6567bb6492224a13ad96cdcc70bac5de2020-11-24T21:11:59ZengBMCBMC Health Services Research1472-69632011-01-01111410.1186/1472-6963-11-4Preventing hospital admissions by reviewing medication (PHARM) in primary care: design of the cluster randomised, controlled, multi-centre PHARM-studyvan den Bogert Sander CAGoudswaard Alex NJonkhoff Andries Rde Koning Fred HPLeendertse Anne Jde Gier Han JEgberts Toine CGvan den Bemt Patricia MLA<p>Abstract</p> <p>Background</p> <p>Medication can be effective but can also be harmful and even cause hospital admissions. Medication review or pharmacotherapy review has often been proposed as a solution to prevent these admissions and to improve the effectiveness and safety of pharmacotherapy. However, most published randomised controlled trials on pharmacotherapy reviews showed no or little effect on morbidity and mortality. Therefore we designed the PHARM (Preventing Hospital Admissions by Reviewing Medication)-study with the objective to study the effect of the total pharmaceutical care process on medication related hospital admissions and on adverse drug events, survival and quality of life.</p> <p>Methods/Design</p> <p>The PHARM-study is designed as a cluster randomised, controlled, multi-centre study in an integrated primary care setting. Patients with a high risk of a medication related hospital admission are included in the study with randomisation at GP (general practitioner) level. We aim to include 14200 patients, 7100 in each arm, from at least 142 pharmacy practices.</p> <p>The intervention consists of a patient-centred, structured, pharmaceutical care process. This process consists of several steps, is continuous and occurrs over multiple encounters of patients and clinicians. The steps of this pharmaceutical care process are a pharmaceutical anamnesis, a review of the patient's pharmacotherapy, the formulation and execution of a pharmaceutical care plan combined with the monitoring and follow up evaluation of the care plan and pharmacotherapy. The patient's own pharmacist and GP carry out the intervention. The control group receives usual care.</p> <p>The primary outcome of the study is the frequency of hospital admissions related to medication within the study period of 12 months of each patient. The secondary outcomes are survival, quality of life, adverse drug events and severe adverse drug events. The outcomes will be analysed by using mixed-effects Cox models.</p> <p>Discussion</p> <p>The PHARM-study is one of the largest controlled trials to study the effectiveness of the total pharmaceutical care process. The study should therefore provide evidence as to whether such a pharmaceutical care process should be implemented in the primary care setting.</p> <p>Trial Registration</p> <p>Trial number: NTR 2647</p> http://www.biomedcentral.com/1472-6963/11/4
collection DOAJ
language English
format Article
sources DOAJ
author van den Bogert Sander CA
Goudswaard Alex N
Jonkhoff Andries R
de Koning Fred HP
Leendertse Anne J
de Gier Han J
Egberts Toine CG
van den Bemt Patricia MLA
spellingShingle van den Bogert Sander CA
Goudswaard Alex N
Jonkhoff Andries R
de Koning Fred HP
Leendertse Anne J
de Gier Han J
Egberts Toine CG
van den Bemt Patricia MLA
Preventing hospital admissions by reviewing medication (PHARM) in primary care: design of the cluster randomised, controlled, multi-centre PHARM-study
BMC Health Services Research
author_facet van den Bogert Sander CA
Goudswaard Alex N
Jonkhoff Andries R
de Koning Fred HP
Leendertse Anne J
de Gier Han J
Egberts Toine CG
van den Bemt Patricia MLA
author_sort van den Bogert Sander CA
title Preventing hospital admissions by reviewing medication (PHARM) in primary care: design of the cluster randomised, controlled, multi-centre PHARM-study
title_short Preventing hospital admissions by reviewing medication (PHARM) in primary care: design of the cluster randomised, controlled, multi-centre PHARM-study
title_full Preventing hospital admissions by reviewing medication (PHARM) in primary care: design of the cluster randomised, controlled, multi-centre PHARM-study
title_fullStr Preventing hospital admissions by reviewing medication (PHARM) in primary care: design of the cluster randomised, controlled, multi-centre PHARM-study
title_full_unstemmed Preventing hospital admissions by reviewing medication (PHARM) in primary care: design of the cluster randomised, controlled, multi-centre PHARM-study
title_sort preventing hospital admissions by reviewing medication (pharm) in primary care: design of the cluster randomised, controlled, multi-centre pharm-study
publisher BMC
series BMC Health Services Research
issn 1472-6963
publishDate 2011-01-01
description <p>Abstract</p> <p>Background</p> <p>Medication can be effective but can also be harmful and even cause hospital admissions. Medication review or pharmacotherapy review has often been proposed as a solution to prevent these admissions and to improve the effectiveness and safety of pharmacotherapy. However, most published randomised controlled trials on pharmacotherapy reviews showed no or little effect on morbidity and mortality. Therefore we designed the PHARM (Preventing Hospital Admissions by Reviewing Medication)-study with the objective to study the effect of the total pharmaceutical care process on medication related hospital admissions and on adverse drug events, survival and quality of life.</p> <p>Methods/Design</p> <p>The PHARM-study is designed as a cluster randomised, controlled, multi-centre study in an integrated primary care setting. Patients with a high risk of a medication related hospital admission are included in the study with randomisation at GP (general practitioner) level. We aim to include 14200 patients, 7100 in each arm, from at least 142 pharmacy practices.</p> <p>The intervention consists of a patient-centred, structured, pharmaceutical care process. This process consists of several steps, is continuous and occurrs over multiple encounters of patients and clinicians. The steps of this pharmaceutical care process are a pharmaceutical anamnesis, a review of the patient's pharmacotherapy, the formulation and execution of a pharmaceutical care plan combined with the monitoring and follow up evaluation of the care plan and pharmacotherapy. The patient's own pharmacist and GP carry out the intervention. The control group receives usual care.</p> <p>The primary outcome of the study is the frequency of hospital admissions related to medication within the study period of 12 months of each patient. The secondary outcomes are survival, quality of life, adverse drug events and severe adverse drug events. The outcomes will be analysed by using mixed-effects Cox models.</p> <p>Discussion</p> <p>The PHARM-study is one of the largest controlled trials to study the effectiveness of the total pharmaceutical care process. The study should therefore provide evidence as to whether such a pharmaceutical care process should be implemented in the primary care setting.</p> <p>Trial Registration</p> <p>Trial number: NTR 2647</p>
url http://www.biomedcentral.com/1472-6963/11/4
work_keys_str_mv AT vandenbogertsanderca preventinghospitaladmissionsbyreviewingmedicationpharminprimarycaredesignoftheclusterrandomisedcontrolledmulticentrepharmstudy
AT goudswaardalexn preventinghospitaladmissionsbyreviewingmedicationpharminprimarycaredesignoftheclusterrandomisedcontrolledmulticentrepharmstudy
AT jonkhoffandriesr preventinghospitaladmissionsbyreviewingmedicationpharminprimarycaredesignoftheclusterrandomisedcontrolledmulticentrepharmstudy
AT dekoningfredhp preventinghospitaladmissionsbyreviewingmedicationpharminprimarycaredesignoftheclusterrandomisedcontrolledmulticentrepharmstudy
AT leendertseannej preventinghospitaladmissionsbyreviewingmedicationpharminprimarycaredesignoftheclusterrandomisedcontrolledmulticentrepharmstudy
AT degierhanj preventinghospitaladmissionsbyreviewingmedicationpharminprimarycaredesignoftheclusterrandomisedcontrolledmulticentrepharmstudy
AT egbertstoinecg preventinghospitaladmissionsbyreviewingmedicationpharminprimarycaredesignoftheclusterrandomisedcontrolledmulticentrepharmstudy
AT vandenbemtpatriciamla preventinghospitaladmissionsbyreviewingmedicationpharminprimarycaredesignoftheclusterrandomisedcontrolledmulticentrepharmstudy
_version_ 1716751912755265536